2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Diseases, Immunology, Neutropenia, Infectious Diseases, Lymphoid Malignancies, Lymphomas, Myeloid Malignancies, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Young Adult
PAPER

5316 Odronextamab (odro) monotherapy in patients (pts) with previously untreated high-risk follicular lymphoma (FL): Long-term follow-up from part 1 (safety lead-in) of the Phase 3 OLYMPIA-1 study

Joshua D. Brody, MD, David Belada, MD, PhD2, Michal Kwiatek, MD, PhD3, Ernesto Pérez Persona4, Gerardo Musuraca, MD, PhD5, Aránzazu Alonso Alonso, MD6, Monica Tani7, Fevzi Altuntas, MD8, Mustafa N. Yenerel, MD9, Ruemu Ejedafeta Birhiray, MD10, Yuan Cheng, PhD11, Priya Deshpande, MSc12, Hesham Mohamed, MD13, Ashish Risal, MD, MS, MHA14, Wojciech Jurczak, MD, PhD15
1 Icahn School of Medicine at Mount Sinai, New York, New York, United States
2 University Hospital and Faculty of Medicine, Hradec Králové, Czech Republic
3 AidPort Clinical Trials Hospital, Skórzewo, Poland
4 University Hospital of Navarre, Pamplona, Spain
5 Romagna Scientific Institute for the Study and Treatment of Tumors (IRST) “Dino Amadori,” IRCCS, Meldola, Italy
6 University Hospital Quironsalud Madrid, Madrid, Spain
7 Santa Maria delle Croci Hospital, Ravenna, Italy
8 Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey
9 Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey
10 Hematology Oncology of Indiana and American Oncology Network, Indianapolis, IN, United States
11 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
12 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
13 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
14 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
15 Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland

Introduction

Odro, a CD20×CD3 bispecific antibody, demonstrated compelling efficacy and a generally manageable safety profile in heavily pretreated pts with relapsed/refractory FL in ELM-2 (NCT03888105; Kim TM, et al. Ann Oncol 2024), supporting its evaluation as a chemotherapy-free frontline option. OLYMPIA-1 (NCT06091254) is a Phase 3, open-label, multicenter study of odro in pts with previously untreated Grade (Gr) 1–3a FL. The study consists of Part 1 (safety lead-in) and Part 2 (randomized study of odro monotherapy vs standard chemoimmunotherapy), where complete response at 30 months (CR30) is the key efficacy endpoint. Initial Part 1 results showed no dose-limiting toxicities (DLTs) and encouraging early responses at Week (Wk) 12 (92.3% CR) in high-risk FL (Brem E, et al. ASH 2024). We report long-term follow-up data, including extended safety and durability of response, from Part 1.

Methods

In OLYMPIA-1 Part 1, pts aged ≥18 years (y) with previously untreated CD20+ Gr 1–3a FL, ECOG PS 0–2, high-risk disease (FLIPI 3–5), and who were eligible for treatment based on the GELF criteria were enrolled.

During induction, pts received 6 × 21-day cycles (Cs) of odro. Step-up dosing (0.7/4/20 mg) was used in C1 with steroid prophylaxis to mitigate the risk of cytokine release syndrome (CRS) and no mandated hospitalization was required. Pts then received odro at 80 and 160 mg in C2–4 and C5–6, respectively. Pts with a CR or partial response at the end of C6 entered a fixed-dose maintenance phase where they received odro monotherapy 320 mg every 8 wks for up to 12 doses (~2 y). All pts received Pneumocystis jirovecii pneumonia prophylaxis.

The Part 1 primary endpoints were incidence of DLTs during the DLT observation period and incidence and severity of TEAEs. Secondary and exploratory endpoints included ORR (assessed by local investigators per Lugano classification) and biomarker analyses.

Results

At data cut-off (DCO; June 2, 2026), 13 pts were enrolled (median age: 62 y; 7 male pts). All pts had FLIPI scores of 3–5, 3 pts had bulky disease, and ECOG PS was 0 in 8 pts and 1 in 5 pts. Two pts had completed treatment and 6 remained on treatment (median follow-up: 22.8 months; 95% CI 17.6–26.3).

No DLTs were observed in the 12 pts included in the DLT analysis set. Thirteen pts had TEAEs (any Gr); the most common were CRS (n=8; Gr 1/2), diarrhea (n=7), and rash/pyrexia (n=5 each). Gr ≥3 TEAEs occurred in 8 pts; the most common were neutropenia (n=3) and increased ALT/AST (n=2 each). Infections occurred in 8 pts and most were low Gr; 3 Gr 3 infections were reported in 2 pts (respiratory tract infection, influenza, and pneumonia).

At Wk 12, 12 pts (92.3%; 95% CI 64.0–99.8) who achieved an ORR had a CR. One pt discontinued treatment due to a TEAE before the Wk 12 tumor assessment. At DCO, 1 pt had completed the CR30 assessment and remained in CR; 6/6 pts who remained on treatment also maintained CR; 1 pt experienced progressive disease at Wk 48 and discontinued the treatment; and 3 other pts maintained CR at the time of early treatment discontinuation.

Biomarker analyses showed that all 11 pts with available baseline CD20 data had CD20 expression in 100% of tumor cells with 2+ or 3+ staining intensity. Baseline ctDNA was detectable in 10/13 evaluable pts. During treatment, 7/10 pts had very low/undetectable ctDNA levels, 3 cleared ctDNA early and maintained clearance, 1 cleared late and maintained clearance, 1 cleared early with later time points pending, and 2 had intermittent detectable/undetectable results.

Conclusions

This long-term follow-up of the OLYMPIA-1 safety lead-in demonstrates that fixed-duration odro monotherapy continues to be well tolerated in pts with previously untreated high-risk FL with no new safety signals. Ongoing CRs were observed at DCO, and the 1 pt who reached the CR30 assessment remained in CR. Emerging efficacy and safety results support the continued evaluation of odro monotherapy in this setting as a chemotherapy-free option. Preliminary ctDNA dynamics were concordant with clinical responses, and all evaluable baseline samples demonstrated strong CD20 expression. Although limited by the small cohort, these findings support the ongoing randomized portion of OLYMPIA-1, which has reopened for enrollment to increase power for PFS (key secondary endpoint), while evaluating CR30 by ICR (primary endpoint) in the first 446 randomized pts. Further biomarker response analyses will be presented.

Joshua D. Brody, MD: Janssen - Honoraria; Innate Pharma SA - Honoraria; Asgaard Therapeutics - Research Funding; Roche - Research Funding; AstraZeneca - Research Funding; Merck - Research Funding; Corvus Pharmaceuticals - Research Funding; Pfizer/Seagen - Research Funding; Genentech - Research Funding; AbbVie - Research Funding; Kite/Gilead - Research Funding; Genmab - Research Funding; BMS - Research Funding; ADC Therapeutics - Research Funding; Asgaard Therapeutics - Consultancy (Includes expert testimony); ADC Therapeutics - Consultancy (Includes expert testimony); Innate Pharma SA - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); Epizyme - Consultancy (Includes expert testimony); Roche - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); Kite/Gilead - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony); BeiGene - Consultancy (Includes expert testimony); Pfizer/Seagen - Consultancy (Includes expert testimony); The Tisch Cancer Institute at Mount Sinai / IcahnSchool of Medicine - Current Employment